A CLINICAL PHARMACOLOGICAL APPROACH TO THE RATIONAL USE OF DRUGS IN BRONCHOOBSTRUCTIVE SYNDROME
Keywords:
broncho-obstructive syndrome, acute respiratory viral infections, combined bronchodilators, Berodual N.Abstract
The role of acute respiratory viral infections (ARVI) in the development of broncho-obstructive syndrome (BOS) is discussed. The main pathogenetic mechanisms of obstructive airway damage, the role of muscarinic cholinergic receptors and β2-adrenergic receptors are described. Methods of treatment of biofeedback in acute respiratory viral infections are discussed in detail. Particular attention is paid to the use of combined bronchodilators in the form of a metered-dose aerosol inhaler, in particular the combination of fenoterol and ipratropium (Berodual N). It was concluded that the combined use of two classes of bronchodilators is more effective in many clinical situations.
References
Joos G.F. et al. // Clin. Exp. Allergy. 2010. V. 30. Suppl. 1. P. 60.
Mannino D.M. et al. // MMWR Surveillance Summaries. 2015. V. 51. P. 1.
Hall W.J., Hall C.B. // Chest. 2019. V. 76. No. 4. P. 458.
Barnes P.J. //Am. J. Med. 2014. V. 117. Suppl. 12A. P. 24S.
Rack´e K., Matthiesen S. // Pulm. Pharmacol. Ther. 2014. V. 17. No. 4. P. 181.
Rosenbaum D.M. et al. // Science. 2017. V. 318. No. 5854. P. 1266.
